Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices- Hagens Berman
At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.99% to $684.87 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.76% to ...
MarketBeat on MSN4d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...
REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
Long Island Press8h
Mineola Board of Ed recognizes Regeneron Scholars, music students
The Mineola Board of Education recognized Fatimah Badoolah, a senior at Mineola High School, who is a 2025 Regeneron Science ...
FierceBiotech7d
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
BioPharma Dive6d
Regeneron gene therapy helps deaf children hear in small study
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
BioSpace7d
Regeneron’s Gene Therapy Restores Hearing in Patients with Rare Genetic Deafness
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...
NASDAQ:REGN Lawsuit Notice: Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Should Contact the Shareholders Foundation
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...